Filterable News List

NEW YORK, NY and ITASKA, IL, November 2, 2026 - tZERO Group, Inc., a financial technology company powering tokenized financial markets through regulated Infrastructure-as-a-Service solutions, and FG Imperii Acquisition Corp. (Nasdaq: FGII), a publicly traded special purpose acquisition company, announced that they have entered into a definitive business combination agreement.

The proposed transaction values tZERO at a pre-money equity valuation of $350 million, including up to $25 million to be realized upon the achievement of specified milestones. Existing tZERO shareholders are expected to roll 100 percent of their equity interests into the combined company. Following the closing, the combined company common stock is expected to trade on NYSE American under the ticker symbol TZRO.

The combined company may receive up to approximately $231 million of cash held in FG Imperii trust account, subject to redemptions and transaction expenses. An affiliate of FG Imperii has also provided additional capital to tZERO previously announced funding round and entered into a term sheet for a forward purchase agreement.

Key Highlights

• Diversified regulated infrastructure across the asset lifecycle including tokenization, transfer agent, brokerage, trading, custody, clearing, and settlement capabilities.
• Established regulatory foundation operating through multiple regulated entities.
• More than a decade of digital market experience since 2014.
• Infrastructure-as-a-Service growth model offering API and white label solutions for B2B and B2B2C partners.

Kuala Lumpur, Malaysia - Bradbury Capital Inc. (NASDAQ: BBCI and BBCIW) announced an adjustment to the exercise price and the redemption trigger price of its outstanding public warrants following the completion of a USD 5 million PIPE financing.The adjustments were triggered in accordance with Section 4.6 of the Warrant Agreement following a business combination and…

… Read on — Pro Members

BOSTON, USA - Seaport Therapeutics, Inc. (Nasdaq: SPTX), a clinical-stage therapeutics company, announced its financial results for the third quarter of 2026, alongside significant corporate and clinical advancements. The company highlighted positive clinical milestones for its neuropsychiatric drug candidates, GlyphAllo and GlyphAgo, and reported a robust cash position expected to fund operations into 2029.

Daphne Zohar, Co-Founder and Chief Executive Officer, emphasized the company's progress, stating, "Over the last few months, Seaport met two key clinical milestones - we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial." She noted that Seaport is now advancing two Phase 2 programs and is well-capitalized to pursue its mission of developing better medicines for mental illness.

Key Clinical Progress

GlyphAllo Program for Major Depressive Disorder (MDD):

• Positive Phase 1 Driving Simulation Data: Seaport announced positive topline data from a Phase 1 trial in healthy volunteers, demonstrating that evening dosing of GlyphAllo (375 mg) did not impair next-morning driving performance compared to placebo. A 250 mg dose also showed no impairment. The drug was well-tolerated.
• Phase 2b BUOY-1 Trial On Track: Enrollment is progressing as planned for the global, randomized, double-blind, placebo-controlled Phase 2b BUOY-1 trial in MDD patients. Topline data from this potentially registration-enabling trial are anticipated in the first half of 2027.

GlyphAgo Program for Generalized Anxiety Disorder (GAD):

• Phase 2a Proof-of-Pharmacology Trial Initiated: The first patient has been dosed in a Phase 2a trial evaluating GlyphAgo's effects on sleep and anxiety severity in GAD patients with sleep disturbance. Topline data are expected in early 2028.
• Planned Phase 2/3 Trial: Seaport plans to initiate a global, randomized, double-blind, placebo-controlled, potentially registration-enabling Phase 2/3 trial for GlyphAgo in GAD in the first half of 2027, with topline data expected by year-end 2028.
• Pharmacokinetic Data Presented: Detailed Phase 1 pharmacokinetic data showed dose-dependent increases in agomelatine exposure, no food effect, and no accumulation over seven days, reinforcing significantly increased bioavailability and reduced PK variability compared to unmodified agomelatine.

Preclinical Programs:

• Glyph2BLSD (SPT-348): The development of this non-hallucinogenic neuroplastogen for neuropsychiatric and headache disorders is on track, with first-in-human-enabling studies expected to be completed by year-end 2027.

Third Quarter 2026 Financial Highlights

Financial Overview:

• Cash Position: As of September 30, 2026, cash, cash equivalents, and investments totaled 403.8 million USD. This is expected to fund operations into 2029, covering three upcoming mid-to-late-stage clinical data readouts.
• R&D Expenses: Research and development expenses increased to 23.9 million USD for Q3 2026, up from 20.5 million USD in Q3 2025, primarily due to the advancement of the GlyphAllo Phase 2b BUOY-1 trial.
• G&A Expenses: General and administrative expenses rose to 6.5 million USD for Q3 2026, compared to 5.0 million USD in Q3 2025, mainly due to increased costs associated with operating as a public company.
• Net Loss: The net loss for Q3 2026 was 26.4 million USD, compared to a net loss of 22.5 million USD for Q3 2025.

Piscataway, New Jersey, United States -- BHAV Acquisition Corp II announced the closing of its initial public offering of 10,000,000 units at an offering price of $10.00 per unit, trading on the Nasdaq Global Market under the ticker symbol BHAIU.Concurrently with the closing of the offering, the company completed a private placement of 225,000 private…

… Read on — Pro Members

Piscataway, New Jersey, United States - BHAV Acquisition Corp II announced the execution of an administrative services agreement with BHAV Partners II LLC, its sponsor, dated October 28, 2026.Per the agreement, the sponsor or its affiliates will provide office space, administrative, and support services to the company. In return, the company will pay a monthly…

… Read on — Pro Members

Shenzhen, China, Oct. 19, 2026 -- Lianhe Sowell International Group Ltd (Nasdaq: LHSW), a provider of industrial machine vision products and solutions in China, announced that its subsidiary, Shenzhen Sowell Technology Development Co., Ltd., has secured a major sales contract with NMS Robotics Sdn. Bhd. in Malaysia.

Contract Details

The agreement involves the supply of 80 sets of Sowell Precision Vision AI Spraying Robots, with a total contract value of RMB23.84 million. The systems are designed for automotive aftermarket spray painting applications and combine nine-axis coordinated motion, 3D vision, and precision spraying technology.

In addition to the Malaysian order, Shenzhen Sowell secured its first order in the United Kingdom with Rowley Spraybooths Midlands Ltd for one AI spraying robot equipped with advanced automated systems.

Transaction Highlights

• RMB23.84 million order for 80 AI spray painting robots in Malaysia.
• First market entry and sales contract in the United Kingdom.
• Expansion of intelligent equipment in the global automotive aftermarket.

Mt. Laurel Township, NJ, USA - Leader's Advantage Acquisition Corp. announced the closing of its sale of an additional 650,000 units pursuant to the partial exercise of the underwriter's over-allotment option in connection with its initial public offering.The units were sold at a price of $10.00 per unit, generating additional gross proceeds of approximately $6,500,000.Total…

… Read on — Pro Members

KUALA LUMPUR, Malaysia, Oct. 05, 2026 -- Ruanyun Edai Technology Inc. (NASDAQ: RYET) announced that it has signed a definitive agreement to grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) an exclusive license for its Cogni AI document-intelligence platform in Malaysian healthcare, alongside a reciprocal share exchange. The agreement marks the expansion of Cogni AI into a new industry and market outside China, aligning with Malaysia's ongoing efforts to accelerate public healthcare digitalization.

Under the terms of the agreement, RYET will be entitled to a 10 percent royalty on qualifying technology receipts collected by BGLC and its affiliates. In addition, BGLC will issue 560,000 shares at closing, including 150,000 shares in exchange for 500,000 new RYET ordinary shares, establishing a direct reciprocal stake between the partners.

Key Agreement Details

• License Terms: An initial ten-year term, renewable at BGLC's option for two additional five-year terms, totaling up to 20 years of exclusive rights in Malaysian healthcare.
• Consideration and Shares: BGLC will issue 410,000 common shares for the license, valued contractually at USD 3.5 million, plus the additional share exchange.
• Royalties and Expansion: A 10 percent royalty applies to qualifying receipts, with options for BGLC to expand the technology into other local industries such as education.

Emeryville, California, USA - OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology, reported its financial results for the third quarter ended September 30, 2026, and raised its full-year financial guidance.

Financial Results

For the third quarter of 2026, total revenue reached $4.0 million compared to $2.2 million for the same period in 2025. The growth was primarily driven by increases in service revenue and xPloration revenue. Net loss for the quarter stood at $15.7 million, or $0.12 per share, compared to a net loss of $16.5 million, or $0.14 per share, in the prior-year period. As of September 30, 2026, the company held $64.2 million in cash, cash equivalents, and short-term investments.

Financial Highlights

• Revenue increased to $4.0 million in Q3 2026 from $2.2 million in Q3 2025.
• Nine-month revenue reached $31.8 million compared to $10.3 million in 2025.
• Cash, cash equivalents, and short-term investments totaled $64.2 million at the end of the quarter.

Guidance Update

Driven by strong business momentum and licensing execution, OmniAb raised its full-year 2026 revenue guidance to a range of $35 million to $39 million, up from the previous range of $32 million to $36 million. The company also adjusted its cash costs and operating expenses guidance to $50 million to $54 million and expects to end the year with cash and cash equivalents between $53 million and $57 million.

HOUSTON, USA - Flowco Holdings Inc. (NYSE: FLOC), a leading provider of production optimization, artificial lift, and emissions management solutions for the oil and natural gas industry, announced that its Board of Directors has approved a quarterly cash dividend.

Dividend Details

The company declared a quarterly cash dividend of $0.09 per share of Class A common stock. The dividend is scheduled to be paid on November 24, 2026, to stockholders of record as of the close of business on November 13, 2026.

Subsidiary Distribution

Additionally, Flowco MergeCo LLC, the operating subsidiary of the company, will issue a corresponding distribution of $0.09 per unit to the holders of its common units.

• Dividend Amount: $0.09 per share and unit
• Record Date: November 13, 2026
• Payment Date: November 24, 2026

Flowco indicated that while it intends to continue paying regular quarterly cash dividends, future declarations remain subject to board discretion, operational results, financial conditions, capital requirements, and credit agreement restrictions.